IACH Focus on Leukemia 2020 | Future avenues for CAR T-cell therapy in ALL
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses the recent results of CAR T-cell therapy in adult patients with acute lymphoblastic leukemia (ALL). Currently, CAR T-cell therapy for ALL is only approved for children and young adults under the age of 25. Therefore, there are relatively few data available for CAR T-cell therapy in patients who are over 25 years old. Additionally, Prof. Chabannon outlines different avenues that deserve further exploration, such as a full understanding of the mechanisms underlying relapse after CAR T-cell therapy. There also needs to be further research to clarify if patients need consolidation after CAR T-cell therapy. The cost-effectiveness of treatment also needs to be evaluated for the European landscape. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
Disclosures
Sanofi SA, Kite / Gilead, Novartis, Celgene / BMS, Janssen, Bellicum Pharmaceuticals, Terumo BCT: speakers bureau & advisory boards
